Lyell Immunopharma Inc expected to post a loss of $3.58 a share - Earnings Preview

Lyell Immunopharma

05/08/2025 23:31

Lyell Immunopharma Inc LYEL.OQ LYEL.O is expected to  show a fall in quarterly revenue when it reports  results on August 7 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Lyell Immunopharma Inc is for a loss of $3.58 per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Lyell Immunopharma Inc is $11.00, about 3.9% below its last closing price of $11.43

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-3.53
-3.60
-3.60
Met
0
Dec. 31 2025
-2.63
-3.40
-4.00
Missed
-17.6
Sep. 30 2024
-3.79
-4.00
-3.40
Beat
15​
Jun. 30 2024
-4.27
-4.10
-3.60
Beat
12.2
​​Mar. 31 2024
-4.49
-4.20
-4.80
Missed
-14.3
Dec. 31 2023
-4.19
-4.56
-4.00
Beat
12.3​
Sep. 30 2023
-4.77
-5.00
-3.40
Beat
32
Jun. 30 2023
-4.96
-5.47
-3.60
Beat
34.1

This summary was machine generated August 5 at 22:31 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)